medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2021, Number 03

<< Back Next >>

Ginecol Obstet Mex 2021; 89 (03)

Gastrointestinal effect and tolerance of myoinositol vs metformin in the metabolic and hormonal control of patients with polycystic ovary syndrome

Aguilar-Mora ME, Treviño-Báez JD, Castañeda-Díaz M, Martínez-Gaytán V, de la O-Pérez LO

Language: Spanish
References: 22
Page: 222-231
PDF size: 378.29 Kb.


ABSTRACT

Objective: To evaluate the effect of myoinositol soft-gel capsules on HOMA index reduction, metabolic and hormonal control in patients with polycystic ovary syndrome versus metformin and gastrointestinal tolerability of both.
Materials and Methods: Prospective, open-label, non-randomized vs active reference controlled clinical study with parallel group design performed in the Human Reproductive Biology service of the High Specialty Medical Unit 23, IMSS, Monterrey NL, from August 2019 to October 2020, in patients with insulin resistance associated with polycystic ovary syndrome and infertility.
Results: 83 patients were studied: 33 who received 600 mg myoinositol soft-gel capsules orally every 12 h and 50 who took 850 mg metformin every 12 h for 12 weeks. Seventy-five patients completed the study. The myoinositol-treated group had a reduction in HOMA index of 1.49 ± 1.05 (with delta value of change) versus the metformin-treated group of 0.42 ± 0.40 (with equal delta value of change). The difference between the two groups was statistically significant. Other metabolic and hormonal parameters also had favorable outcomes in both groups, but with a superior trend in the myoinositol group.
Conclusions: The advantage of myoinositol treatment in reducing the HOMA index and other metabolic and hormonal parameters in patients with insulin resistance associated with polycystic ovary syndrome and infertility was demonstrated, with good gastrointestinal tolerability.


REFERENCES

  1. Checa MA, Espinós JJ, Matorras R. Síndrome De Ovario Poliquístico. 2da Ed. Madrid, España: Médica Panamericana; 2012; 1-184. https://www.sefertilidad.net/docs/grupos/ endo/LibroOvario.pdf

  2. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction (Oxford, England). 2018 Sep;33(9):1602-1618. DOI: 10.1093/humrep/dey256.

  3. GPC. Síndrome de Ovario Poliquístico, Instituto Mexicano del Seguro Social; Ciudad de México 2013; 1-50. http:// www.imss.gob.mx/sites/all/statics/guiasclinicas/000GER_ OvariosPoliquisticos.pdf

  4. Artini P, Berardino O, Papini F, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013 Apr;29(4):375-9. https://doi.org/10.3109/09513590.20 12.743020

  5. Fruzzetti F, Perini D, Russo M, et al. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2017 Jan;33(1):39-42. https://doi.org/10.1080/0951 3590.2016.1236078

  6. Pkhaladze L, Barbakadze L, Kvashilava N. Myo-inositol in the Treatment of Teenagers Affected by PCOS. Int J Endocrinol. 2016;2016:1473612. https://doi. org/10.1155/2016/1473612

  7. Magendzon A. Anovulación y disfunción ovulatoria e infertilidad. Rev Med Clin Condes. 2010; 21(3):377-386. https:// doi.org/10.1016/S0716-8640(10)70548-4

  8. Sociedad Española de Ginecología Obstetricia. Guía de asistencia práctica. Estudio y tratamiento de la anovulación en el síndrome de ovarios poliquísticos. Prog Obstet Ginecol. 2017;60(5):505-516. https://sego.es/documentos/progresos/ v60-2017/n5/20_7J__Estudio_y_tratamiento_de_la_ Anovulacion_y_del_Sindrome_de_ovario_poliquistico.pdf

  9. Papaleo E, Unfer V, Baillargeon JP. et al. Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction. Gynecol End ocrinol. 2007 Dec; 23 (12): 700-3. https://doi. org/10.1080/09513590701672405

  10. Showell M, Mackenzie R, Jordan V, et al. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018 Dec 20;12(12):CD012378.

  11. Tso L, Costello M, Albuquerque L, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014 Nov 18;2014(11):CD006105. https://doi. org/10.1002/14651858.CD012378.pub2

  12. Unfer V, Facchinetti F, Orrú B, et al. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017 Nov; 6(8): 647–658. DOI: https://doi.org/10.1530/EC-17-0243

  13. Agrawal A, Mahey R, Kachhawa G, et al. Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecol Endocrinol. 2019 Jun;35(6):511- 514. https://doi.org/10.1080/09513590.2018.1549656

  14. Özay ÖE, Özay AC, Çağlıyan E, et al. Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial. Gynecol Endocrinol. 2017 Jul;33(7):524-528. https://doi. org/10.1080/09513590.2017.1296127

  15. Nas K, Túú L. A comparative study between myo-inositol and metformin in the treatment of insulin-resistant women. Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):77-82. https:// www.europeanreview.org/wp/wp-content/uploads/077- 082-A-comparative-study-between-myo-inositol-and-metformin- in-the-treatment-of-insulin-resistant-women.pdf

  16. Baños N, de lal Rosa L, Vallejo CF, et al. Eficacia del Inositol en las mujeres con Síndrome del Ovario Poliquístico y deseo genésico: Revisión sistemática y metaanálisis. Rev Iberoam Fert Rep Hum. 2012 Oct-Dic;29(4):129-137. http://www.revistafertilidad.org/rif/vplus/arts/eficacia% 20inositol.pdf

  17. Kamenov Z, Kolarov G, Gateva A, et al. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol. 2015 Feb;31(2):131- 5. https://doi.org/10.3109/09513590.2014.964640

  18. Carlomagno G, Unfer V, Buffo S, et al. Myo-inositol in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 2011;26(7):526-30. https://doi. org/10.1002/hup.1241

  19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, authors. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25. DOI: 10.1016/j.fertnstert.2003.10.004

  20. Carlomagno G, de Grazia S, Unfer V, et al. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin Drug Deliv. 2012 Feb;9(3):267-71. https://doi.org/10.1517/17425247.2012.662953

  21. Shokrpour M, Foroozanfard F, Ebrahimi FA, et al. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. Gynecol Endocrinol. 2019 May;35(5):406-411. https://doi.org/10.1080/09513 590.2018.1540570

  22. Facchinetti F, Unfer V, Dewailly D, et al. Inositols in Polycystic Ovary Syndrome: An Overview on the Advances. Trends Endocrinol Metab. 2020 Jun;31(6):435-447.




2020     |     www.medigraphic.com